Table 1 of
Wilkinson-Berka, Mol Vis 2007;
13:1529-1538.Table 1 of
Wilkinson-Berka, Mol Vis 2007;
13:1529-1538.
Table 1. Therapies, intervention period, number of animals and body weight at postnatal day 18 in each sham and oxygen induced retinopathy group
The following abbreviations were used: growth hormone receptor (GHr), antisense oligonucleotide (ASO), intraperitoneal (i.p.), and subcutaneous (s.c.). Early intervention is administration at P7, 8, 9, 11, 13, 15, and 17 (total of seven doses). Late intervention is administration at P12-16 (total of five doses). Values are mean±sem. There were no differences in body weights between all groups. Asterisk indicates *mean for four treatment groups.
Body weight
Group Intervention N (g)
------------------------------------ ------------ ---- -----------
Controls
Sham+vehicle i.p. early 9 7.02±0.23
OIR+vehicle i.p. early 9 6.88±0.30
Sham+vehicle i.p. late 9 6.63±0.22
OIR+vehicle i.p. late 9 6.79±0.21
ATL 227446 - GHr ASO
Sham+5, 10, 20, 30 mg/kg i.p. early 9-10 *6.42±0.25
Sham+5, 10, 20, 30 mg/kg i.p. late 8-10 *6.34±0.21
OIR+5, 10, 20, 30 mg/kg i.p. early 9-10 *6.93±0.18
OIR+5, 10, 20, 30 mg/kg i.p. late 9-10 *6.55±0.28
Octreotide
Sham+20 mg/kg/bi-daily s.c. late 10 6.79±0.17
OIR+20 mg/kg/bi-daily s.c. late 10 6.48±0.39
ATL 261303 - control oligonucleotide
Sham+20 mg/kg i.p. early 9 6.64±0.23
Sham+20 mg/kg i.p. late 9 6.33±0.25
OIR+20 mg/kg i.p. early 10 6.71±0.19
OIR+20 mg/kg i.p. late 9 7.12±0.34
ATL 260120 control oligonucleotide
Sham+20 mg/kg i.p. early 9 6.58±0.28
Sham+30 mg/kg i.p. early 9 6.81±0.22
OIR+20 mg/kg i.p. early 7 6.36±0.18
OIR+30 mg/kg i.p. early 9 7.12±0.21
|